Impact of the serum creatinine and cystatin C ratio for prediction of sarcopenia and prognosis in biliary tract cancer
- PMID: 38683456
- DOI: 10.1007/s10147-024-02539-7
Impact of the serum creatinine and cystatin C ratio for prediction of sarcopenia and prognosis in biliary tract cancer
Abstract
Background: Sarcopenia is a poor prognostic factor in cancer patients. In recent years, there have been reports that serum creatinine and cystatin C (Cr/CysC) ratio is associated with sarcopenia. However, the prognostic value of the Cr/CysC ratio in biliary tract cancer is unclear. We evaluated the impact of the Cr/CysC ratio on sarcopenia and prognosis in biliary tract cancer.
Methods: We retrospectively reviewed the records of 190 patients with biliary tract cancer who had undergone surgical resection from January 2017 to March 2023. Frozen serum samples collected at the time of surgery were used to measure CysC. We calculated the Cr/CysC ratio and investigated the relationship with sarcopenia and the prognostic significance.
Results: We calculated the cutoff value of the Cr/CysC ratio for low skeletal muscle index (SMI) (< 42 cm2/m2 for males and < 38 cm2/m2 for females). The optimal cutoff value of the Cr/CysC ratio was 0.848. The low Cr/CysC ratio group was significantly associated with higher preoperative CRP and lower albumin, lower SMI, lower handgrip strength, and higher intramuscular adipose tissue content. In multivariate analysis, patients with a low Cr/CysC ratio showed poorer overall survival (hazard ratio 2.60, 95% confidence interval 1.07-6.29, p = 0.033), which was significantly worse than in those with a high Cr/CysC ratio.
Conclusions: In patients with biliary tract cancer, the Cr/CysC ratio showed weak correlation with sarcopenic indicators. However, the Cr/CysC ratio could be strong prognostic factor in biliary tract cancer.
Keywords: Biliary tract cancer; Creatinine; Creatinine and cystatin C ratio; Cystatin C; Prognosis; Sarcopenia.
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Similar articles
-
Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease.Clin Nutr. 2021 Mar;40(3):1274-1280. doi: 10.1016/j.clnu.2020.08.010. Epub 2020 Aug 19. Clin Nutr. 2021. PMID: 32863062
-
Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer.BMC Gastroenterol. 2022 Jan 19;22(1):26. doi: 10.1186/s12876-022-02093-4. BMC Gastroenterol. 2022. PMID: 35045814 Free PMC article.
-
Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours.Front Nutr. 2022 Sep 2;9:963265. doi: 10.3389/fnut.2022.963265. eCollection 2022. Front Nutr. 2022. PMID: 36118766 Free PMC article.
-
Diagnostic test accuracy of serum creatinine and cystatin C-based index for sarcopenia: a systematic review and meta-analysis.Age Ageing. 2024 Jan 2;53(1):afad252. doi: 10.1093/ageing/afad252. Age Ageing. 2024. PMID: 38251741
-
Preoperative C-reactive protein-to-albumin ratio as a prognostic factor in biliary tract cancer: A systematic review and meta-analysis.Medicine (Baltimore). 2023 Jun 2;102(22):e33656. doi: 10.1097/MD.0000000000033656. Medicine (Baltimore). 2023. PMID: 37266653 Free PMC article.
Cited by
-
Expression profiles and clinical significance of cystatin family genes in transitional cell carcinoma of the urinary bladder.Bladder (San Franc). 2025 Mar 13;12(1):e21200035. doi: 10.14440/bladder.2024.0057. eCollection 2025. Bladder (San Franc). 2025. PMID: 40747123 Free PMC article.
-
Combined effect of frailty and sarcopenia on postoperative complications in older adults undergoing curative surgery for hepato-biliary-pancreatic cancer.Ann Gastroenterol Surg. 2024 Dec 24;9(3):587-594. doi: 10.1002/ags3.12897. eCollection 2025 May. Ann Gastroenterol Surg. 2024. PMID: 40385335 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous